---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-23-000025"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T02:55:15.896812+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lilly Q4 2022 EPS $2.14; revenue down 9%; core up 5%; 2023 guidance $7.90-$8.10

## Summary
- Q4 2022 revenue $7.30B (-9% YoY); ex-COVID antibodies revenue +5% (+10% constant currency).
- Reported EPS $2.14 (+13%); non-GAAP EPS $2.09 (-4%); includes $0.23 acquired IPR&D charges.
- Key growth products (Verzenio, Mounjaro, Jardiance, Taltz, Trulicity, etc.) grew 21% to 70% of revenue.
- 2023 EPS guidance: reported $7.90-$8.10; non-GAAP $8.35-$8.55; mid-teen core revenue growth expected.
- Pipeline: FDA approved Jaypirca for MCL; rolling submission tirzepatide in obesity; Jardiance CKD submissions.

## SEC filing metadata
- accession: 0000059478-23-000025
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947823000025/0000059478-23-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947823000025/lly-20230202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-23-000025
- JSON: https://secwatch.observer/filing/0000059478-23-000025.json
- Plain text: https://secwatch.observer/filing/0000059478-23-000025.txt

## Key facts
- Earnings Releases
  ELI LILLY & Co reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 2, 2023, announcing the financial results of Eli Lilly and Company for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/59478/000005947823000025/0000059478-23-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.